Humana Inc. (NYSE:HUM – Get Rating) insider Joseph C. Ventura sold 1,226 shares of the business’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $506.78, for a total transaction of $621,312.28. Following the sale, the insider now directly owns 3,930 shares of the company’s stock, valued at approximately $1,991,645.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Humana Trading Up 0.7 %
Shares of HUM stock traded up $3.28 during trading hours on Thursday, hitting $493.91. The company had a trading volume of 1,005,019 shares, compared to its average volume of 1,026,274. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.53 and a quick ratio of 1.53. The stock has a market capitalization of $62.51 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.46 and a beta of 0.77. The company’s fifty day moving average is $487.24 and its 200 day moving average is $460.51. Humana Inc. has a fifty-two week low of $351.20 and a fifty-two week high of $514.98.
Humana (NYSE:HUM – Get Rating) last released its quarterly earnings results on Wednesday, July 27th. The insurance provider reported $8.67 EPS for the quarter, topping analysts’ consensus estimates of $7.67 by $1.00. Humana had a return on equity of 18.42% and a net margin of 3.52%. The company had revenue of $23.66 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the prior year, the firm earned $6.89 earnings per share. The firm’s revenue was up 14.6% compared to the same quarter last year. Research analysts expect that Humana Inc. will post 24.97 earnings per share for the current fiscal year.
Humana Announces Dividend
Analysts Set New Price Targets
Several research firms have commented on HUM. Oppenheimer boosted their price objective on Humana from $520.00 to $550.00 and gave the stock an “outperform” rating in a research note on Friday, September 16th. Deutsche Bank Aktiengesellschaft raised their price objective on Humana from $450.00 to $514.00 in a report on Thursday, July 28th. StockNews.com lowered shares of Humana from a “strong-buy” rating to a “buy” rating in a report on Friday, July 29th. SVB Leerink raised their price target on shares of Humana from $535.00 to $540.00 and gave the stock an “outperform” rating in a research note on Thursday, July 28th. Finally, Morgan Stanley raised shares of Humana from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $494.00 to $549.00 in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Moderate Buy” and an average target price of $519.28.
Institutional Trading of Humana
Institutional investors and hedge funds have recently bought and sold shares of the business. Tcwp LLC acquired a new position in shares of Humana in the first quarter valued at approximately $25,000. Castleview Partners LLC boosted its position in Humana by 46,704.0% in the 2nd quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider’s stock valued at $25,000 after buying an additional 11,676 shares during the period. Jones Financial Companies Lllp acquired a new position in shares of Humana in the second quarter worth $29,000. WFA of San Diego LLC purchased a new stake in shares of Humana during the second quarter worth $30,000. Finally, Riverview Trust Co acquired a new stake in shares of Humana in the first quarter valued at $32,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.